Anixa Biosciences Financials
| ANIX Stock | USD 3.32 0.10 3.11% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.94 | 11.25 |
|
|
Investors should never underestimate Anixa Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Anixa Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Anixa Biosciences.
Net Income |
|
Anixa | Select Account or Indicator |
Understanding current and past Anixa Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Anixa Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Anixa Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Anixa Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anixa Biosciences. Check Anixa Biosciences' Beneish M Score to see the likelihood of Anixa Biosciences' management manipulating its earnings.
Anixa Biosciences Stock Summary
Anixa Biosciences competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Anixa Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US03528H1095 |
| CUSIP | 03528H109 45069V203 217721109 45069V104 |
| Location | California; U.S.A |
| Business Address | 3150 Almaden Expressway, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.anixa.com |
| Phone | 408 708 9808 |
| Currency | USD - US Dollar |
Anixa Biosciences Key Financial Ratios
| Return On Equity | -0.55 | ||||
| Price To Sales | 481.54 X | ||||
| Revenue | 210 K | ||||
| Gross Profit | 127.5 K | ||||
| EBITDA | (10.96 M) |
Anixa Biosciences Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 9.5M | 36.3M | 30.4M | 25.5M | 29.4M | 30.8M | |
| Other Current Liab | 845.8K | 1.1M | 1.7M | 1.8M | 2.0M | 2.1M | |
| Net Debt | (6.4M) | (28.9M) | (12.1M) | (740K) | (666K) | (699.3K) | |
| Retained Earnings | (191.8M) | (204.8M) | (218.4M) | (228.2M) | (205.4M) | (195.1M) | |
| Cash | 6.4M | 29.1M | 12.4M | 915K | 1.1M | 999.6K | |
| Inventory | 1.0 | (2.4M) | (2.6M) | (46K) | (41.4K) | (39.3K) | |
| Other Current Assets | 311.6K | 551.6K | 513K | 1.2M | 1.1M | 1.2M | |
| Total Liab | 1.2M | 1.5M | 2.2M | 2.2M | 2.5M | 2.2M | |
| Total Current Assets | 9.4M | 36.0M | 30.2M | 25.4M | 29.2M | 30.6M | |
| Net Receivables | 66.5K | 2.2K | 46K | 270K | 243K | 231.6K | |
| Accounts Payable | 232.4K | 136K | 265K | 206K | 185.4K | 176.1K | |
| Common Stock | 242.5K | 300.5K | 309K | 311K | 279.9K | 265.9K | |
| Net Tangible Assets | 5.2M | 8.8M | 35.4M | 29.0M | 33.4M | 35.1M | |
| Capital Surpluse | 175.4M | 186.8M | 200.4M | 247.1M | 284.2M | 181.1M |
Anixa Biosciences Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 0.0 | 512.5K | 2.5B | 210K | 241.5K | 229.4K | |
| Gross Profit | (90.2K) | 127.5K | 2.5B | 49K | 56.4K | 53.5K | |
| Operating Income | (10.0M) | (13.1M) | (13.9M) | (11.0M) | (9.9M) | (9.4M) | |
| Ebit | (10.1M) | (13.1M) | (13.8M) | (11.0M) | (9.9M) | (9.4M) | |
| Ebitda | (10.0M) | (13.1M) | (13.7M) | (11.0M) | (9.9M) | (9.4M) | |
| Net Income | (10.1M) | (12.9M) | (13.5M) | (9.8M) | (8.8M) | (9.3M) | |
| Income Tax Expense | 40.2K | (181.3K) | (280K) | (119K) | (136.9K) | (130.0K) | |
| Income Before Tax | (10.1M) | (13.1M) | (13.8M) | (9.9M) | (8.9M) | (9.4M) | |
| Research Development | 4.4M | 6.2M | 6.7M | 4.8M | 5.5M | 3.6M | |
| Cost Of Revenue | 90.2K | 385.0K | 42K | 161K | 185.2K | 175.9K | |
| Interest Income | 33.9K | 2.3K | 104K | 1.1M | 1.2M | 1.3M | |
| Minority Interest | (74.0K) | 173.5K | (176K) | 119K | 136.9K | 143.7K | |
| Net Interest Income | 33.9K | 2.3K | 104K | 1.1M | 1.2M | 1.3M |
Anixa Biosciences Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Anixa Biosciences. It measures of how well Anixa is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Anixa Biosciences brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Anixa had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Anixa Biosciences has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 2.9M | 22.7M | (16.8M) | (11.4M) | (10.3M) | (9.8M) | |
| Free Cash Flow | (6.2M) | (4.9M) | (6.5M) | (6.2M) | (5.6M) | (5.3M) | |
| Depreciation | 90.2K | 59.9K | 42K | 46K | 52.9K | 50.3K | |
| Other Non Cash Items | 148.1K | (5.4K) | 752K | 313K | 360.0K | 549.7K | |
| Net Income | (10.1M) | (13.1M) | (13.8M) | (9.9M) | (8.9M) | (9.4M) | |
| End Period Cash Flow | 6.4M | 29.1M | 12.4M | 915K | 1.1M | 999.6K | |
| Change To Inventory | (271.7K) | (64.3K) | 29K | 224K | 257.6K | 270.5K | |
| Investments | (290K) | (4.0M) | (10.7M) | (5.6M) | (5.0M) | (4.8M) | |
| Change To Netincome | 4.0M | 4.1M | 7.9M | 6.7M | 7.7M | 3.9M |
Anixa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anixa Biosciences's current stock value. Our valuation model uses many indicators to compare Anixa Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anixa Biosciences competition to find correlations between indicators driving Anixa Biosciences's intrinsic value. More Info.Anixa Biosciences is rated second in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Anixa Biosciences' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anixa Biosciences' earnings, one of the primary drivers of an investment's value.Anixa Biosciences Systematic Risk
Anixa Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Anixa Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Anixa Biosciences correlated with the market. If Beta is less than 0 Anixa Biosciences generally moves in the opposite direction as compared to the market. If Anixa Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Anixa Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Anixa Biosciences is generally in the same direction as the market. If Beta > 1 Anixa Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Anixa Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Anixa Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Anixa Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Anixa Biosciences November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Anixa Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Anixa Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Anixa Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Anixa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anixa Biosciences's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.35 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 31.27 | |||
| Value At Risk | (5.74) | |||
| Potential Upside | 6.29 |
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.